TS
DYN icon

Thomas Steyer’s Dyne Therapeutics DYN Stock Holding History

Thomas Steyer’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$181K – 115
2026
Q1 		$181K Hold
10,000
– – ﹤0.01% 151
2025
Q4 		$196K Hold
10,000
– – ﹤0.01% 137
2025
Q3 		$127K Hold
10,000
– – ﹤0.01% 132
2025
Q2 		$95.2K Hold
10,000
– – ﹤0.01% 131
2025
Q1 		$105K Sell
10,000
-219,121
-96% -$3.13M ﹤0.01% 134
2024
Q4 		$5.4M Sell
229,121
-198,879
-46% -$5.88M 0.02% 87
2024
Q3 		$15.4M Buy
428,000
+422,000
+7,033% +$16.8M 0.07% 83
2024
Q2 		$212K Buy
+6,000
New +$174K ﹤0.01% 134
2020
Q4 		– Sell
-200,000
Closed -$4.04M – 143
2020
Q3 		$4.04M Buy
+200,000
New +$4.39M 0.03% 114

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Thomas Steyer's DYN Position: Q2 2026 in Review

Thomas Steyer sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 10,000 shares — an estimated $181K sold.

Thomas Steyer first reported a position in DYN in Q3 2020 and held it in 9 quarters. The position peaked at $15.4M in Q3 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Thomas Steyer reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Thomas Steyer sold 10,000 Dyne Therapeutics shares in Q2 2026, an estimated $181K.
  • Thomas Steyer first reported a position in Dyne Therapeutics in Q3 2020 and held it in 9 quarters.
  • Thomas Steyer's Dyne Therapeutics position peaked at $15.4M in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.